XML 73 R50.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments and Fair Value Measurements (Tables)
 12 Months Ended
Dec. 27, 2024
Fair Value Disclosures [Abstract]  
Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis
The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:
Fair Value Measurement
Using Fair Value Hierarchy:
December 27, 2024 (Successor)Level 1Level 2Level 3
Assets:
Debt and equity securities held in rabbi trusts
$25.4 $17.4 $8.0 $— 
Equity securities
$12.0 $12.0 $— $— 
Interest rate cap
$5.3 $— $5.3 $— 
$42.7 $29.4 $13.3 $— 
Liabilities:
Debt derivative liabilities
$— $— $— $— 
Deferred compensation liabilities$22.5 $— $22.5 $— 
Contingent consideration liabilities$17.5 $— $— $17.5 
$40.0 $— $22.5 $17.5 
Fair Value Measurement
Using Fair Value Hierarchy:
December 29, 2023 (Successor)Level 1Level 2Level 3
Assets:
Debt and equity securities held in rabbi trusts$43.3 $29.1 $14.2 $— 
Equity securities28.9 28.9 — — 
Interest rate cap12.9 — 12.9 — 
$85.1 $58.0 $27.1 $— 
Liabilities:
Debt derivative liabilities$15.1 $— $— $15.1 
Deferred compensation liabilities21.0 — 21.0 — 
Contingent consideration liabilities14.7 — — 14.7 
$50.8 $— $21.0 $29.8 
Schedule of Reconciliation of Changes in Fair Value of Contingent Consideration
The following table summarizes activity for contingent consideration:
Balance as of December 30, 2022 (Predecessor)7.3 
Fair value adjustments(7.2)
Fresh-start adjustment
14.9 
Balance as of November 14, 2023 (Predecessor)$15.0 
Balance as of November 15, 2023 (Successor)$15.0 
Fair value adjustments(0.3)
Balance as of December 29, 2023 (Successor)14.7 
Fair value adjustments2.8 
Balance as of December 27, 2024 (Successor)$17.5 
Schedule of Carrying Amount and Fair Value of Long-term Debt
Successor
December 27, 2024December 29, 2023
Carrying
Value		Fair
Value		Carrying
Value		Fair
Value
Level 1:
14.75% Second-Out Takeback Notes due November 2028$505.4 $511.6 $836.4 $844.4 
Level 2:
First-Out Takeback Term Loan Due November 2028— — 243.4 232.8 
Second-Out Takeback Term Loan Due November 2028410.2 415.4 685.5 654.0 
Total Debt$915.6 $927.0 $1,765.3 $1,731.2 
Schedules of Concentration of Risk
The following table shows net sales attributable to distributors that accounted for 10.0% or more of the Company's total net sales:
SuccessorPredecessor
Year Ended
December 27, 2024		Period from
November 15, 2023
through December 29, 2023		Period from
December 31, 2022
through
November 14, 2023		Period from
June 17, 2022
through
December 30, 2022		Period from
January 1, 2022
through
June 16, 2022
FFF Enterprises, Inc.23.1 %23.1 %22.3 %26.1 %11.8 %
Cencora, Inc. (formerly known as AmerisourceBergen Corp.)13.8 %*10.0 **
McKesson Corporation*10.8 ***
CuraScript, Inc.
****15.6 
* Net sales to this distributor were less than 10.0% of total net sales during the respective periods presented above.
The following table shows accounts receivable attributable to distributors that accounted for 10.0% or more of the Company's gross accounts receivable at the end of each period:
Successor

December 27,
2024		December 29,
2023
Cencora, Inc. (formerly known as AmerisourceBergen Corp.)34.9 %24.2%
McKesson Corporation19.8 20.0
FFF Enterprises12.1 *
* Accounts receivable attributable to this distributor was less than 10.0% of total gross accounts receivable at the end of the respective period presented above.

The following table shows net sales attributable to products that accounted for 10.0% or more of the Company's total net sales:
SuccessorPredecessor
Year Ended
December 27, 2024		Period from
November 15, 2023
through December 29, 2023		Period from
December 31, 2022
through
November 14, 2023		Period from
June 17, 2022
through
December 30, 2022		Period from
January 1, 2022
through
June 16, 2022
Acthar Gel24.5 %23.5 %22.7 %28.3 %25.4 %
INOmax13.2 14.5 16.5 16.7 19.0 
Therakos12.2 16.1 13.6 12.5 12.5 
APAP*13.4 11.4 10.7 11.0